CORRECTION



Correction to: The impact of metformin use on the outcomes of relapse-remitting multiple sclerosis patients receiving interferon beta 1a: an exploratory prospective phase II open-label randomized controlled trial

Mohamed Y. Abdelgaied 1,5 · Mohamed Hamed Rashad 2 · Hend M. El-Tayebi 3 · Mohamed H. Solayman 1,4 D

Published online: 18 March 2024

© The Author(s), under exclusive licence to Springer-Verlag GmbH Germany 2024

Correction to: Journal of Neurology https://doi.org/10.1007/s00415-023-12113-2

In the original version of this article, affiliation details for author Mohamed Y. Abdelgaied were incorrectly given as

¹Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt

³Clinical Pharmacology and Pharmacogenomics Research Group, Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt

⁵Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada

but should have been

The original article can be found online at https://doi.org/10.1007/s00415-023-12113-2.

- Mohamed H. Solayman mohamed.solayman@guc.edu.eg
- Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt
- Neurology Department, Faculty of Medicine, Al-Azhar University, Cairo, Egypt
- ³ Clinical Pharmacology and Pharmacogenomics Research Group, Pharmacology and Toxicology Department, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt
- Clinical Pharmacy Department, Faculty of Pharmacy, Ain Shams University, Cairo, Egypt
- Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada

¹Clinical Pharmacy Department, Faculty of Pharmacy and Biotechnology, The German University in Cairo (GUC), Cairo, Egypt

⁵Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta, Edmonton, AB T6G 2E1, Canada

